Janet Tate

Janet Tate is a **Researcher** at Yale University’s **Yale School of Medicine**, affiliated with the **Veterans Aging Cohort Study (VACS)**. She holds roles including Director of the Biostatistics Core, Co-Director of the Risk Index Workgroup, and Co-Director of the Liver Core at VACS. Her research focuses on biostatistics, epidemiology, and health outcomes in aging populations, particularly veterans with HIV, prostate cancer, and comorbidities. She earned a **ScD in Biostatistics** from Harvard University (2010), an **MPH** from the University of Connecticut (1997), and a **BS** from Southern Connecticut State University (1981).

Dr. Tate’s work emphasizes developing prognostic tools for mortality prediction, such as the VACS-Charlson Index, which guides clinical decision-making in prostate cancer treatment. Her research has been published in journals like *European Urology* and *Frontiers in Medicine*. She serves on editorial boards and as a reviewer for multiple journals, including *Annals of Internal Medicine* and *Pharmacoepidemiology and Drug Safety*.

Her scientific awards include repeated recognition as a **Best Reviewer** (2012, 2015, 2017) and technical achievement awards from Uniroyal Chemical (1987, 1991). She contributes to interdisciplinary teams addressing health disparities, liver cancer screening, and HIV prevention through the **Yale-Drug Use, Addiction, and HIV Prevention Research Scholars (DAHRS)** initiative. Her work aligns with Yale’s focus on translational research and public health equity.